Office of the Director; Notice of Charter Renewal for the National Science Advisory Board for Biosecurity, 26258 [2010-11043]
Download as PDF
<![CDATA[
26258
Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
respondents
Respondents
Instrument type
Eligible participants .........................................
Baseline questionnaire ...................................
Symptom survey ............................................
Scripted commute data collection ..................
Dated: May 5, 2010.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–11180 Filed 5–10–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter
Renewal for the National Science
Advisory Board for Biosecurity
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the Charter for the National
Science Advisory Board for Biosecurity
(NSABB) was renewed for an additional
two-year period on April 7, 2010.
It is determined that NSABB is in the
public interest in connection with the
performance of duties imposed on the
Department of Health and Human
Services by law, and that these duties
can best be performed through the
advice and counsel of this group.
Inquiries may be directed to Jennifer
Spaeth, Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail code 4875), Telephone (301) 496–
2123, or spaethj@od.nih.gov.
Dated: May 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–11043 Filed 5–10–10; 8:45 am]
BILLING CODE 4140–01–P
emcdonald on DSK2BSOYB1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
VerDate Mar<15>2010
19:22 May 10, 2010
Jkt 220001
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Erythroid Progenitor Cell Line for
Hematological Disease Applications
Description of Invention: Plasmodium
vivax (malaria) is a significant health
concern in many parts of Asia, Latin
America, North Africa, and the Middle
East. There is a lack of continuous
culture systems for this pathogen. The
subject technology is an erythroid
progenitor continuous cell line (termed
CD36E) identified by erythroid markers
CD36, CD33, CD44, CD71, CD235, and
globoside. These CD36E cells are
heterozygous for Fya and Fyb (Duffy
antigen). Due to recent evidence that
Plasmodium vivax (P. vivax) can infect
erythroid progenitor cells (reference: YX
Ru et al. and T Panichakul et al.), these
cells can be potentially used for
culturing P. vivax and other species of
malaria. This in turn could aid
development of malaria related
treatments and/or products. In addition,
the cell line can also be used for other
hematological disease applications that
involve red blood cells or red blood cell
precursors. The CD36E cells also
produce alpha, beta, and chi
hemoglobin and therefore may be used
for research involving hemoglobin.
Applications:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
No. of
responses per
respondent
40
40
40
1
5
2
Average
burden per
respondent
(in hours)
20/60
2/60
2
• Culture system for Plasmodium
species (malaria)
• Hematological diseases
Advantages: Immortalized erythroid
progenitor cell line.
Development Status: In vitro data can
be provided upon request.
Market:
• Malaria
• Anti-malaria drug screening
• Hematological diseases
• Hemoglobin
Inventors: Susan Wong, Neal S.
Young, Ning Zhi (NHLBI).
Relevant Publications:
1. YX Ru et al. Invasion of
erythroblasts by Pasmodium vivax: A
new mechanism contributing to malarial
anemia. Ultrastruct Pathol. 2009
Oct;33(5):236–242. [PubMed:
19895296].
2. T Panichakul et al. Production of
erythropoietic cells in vitro for
continuous culture of Plasmodium
vivax. Int J Parasitol. 2007
Dec;37(14):1551–1557. [PubMed:
17610880].
Patent Status: HHS Reference No. E–
151–2010/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: Available for
biological materials licensing.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart Lung and Blood
Institute, Hematology Branch, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the CD36E cell line.
Please contact Cecilia Pazman, Ph.D., at
pazmance@mail.nih.gov for more
information.
Parvovirus B19 Codon Optimized
Structural Proteins for Vaccine and
Diagnostic Applications
Description of Invention: Parvovirus
B19 (B19V) is the only known
pathogenic human parvovirus. Infection
by this viral pathogen can cause
transient aplastic crisis in individuals
with high red cell turnover, pure red
cell aplasia in immunosuppressed
patients, and hydrops fetalis during
E:\FR\FM\11MYN1.SGM
11MYN1
]]>Agencies
[Federal Register Volume 75, Number 90 (Tuesday, May 11, 2010)]
[Notices]
[Page 26258]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-11043]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter Renewal for the
National Science Advisory Board for Biosecurity
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
Charter for the National Science Advisory Board for Biosecurity (NSABB)
was renewed for an additional two-year period on April 7, 2010.
It is determined that NSABB is in the public interest in connection
with the performance of duties imposed on the Department of Health and
Human Services by law, and that these duties can best be performed
through the advice and counsel of this group.
Inquiries may be directed to Jennifer Spaeth, Director, Office of
Federal Advisory Committee Policy, Office of the Director, National
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda,
Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or
spaethj@od.nih.gov.
Dated: May 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-11043 Filed 5-10-10; 8:45 am]
BILLING CODE 4140-01-P
